[Atracurium: neuromuscular blockade in repeated administration].
The neuromuscular blocking action of repeated injections of atracurium and vecuronium was studied in 74 surgical patients during balanced anaesthesia (methohexitone or etomidate, intubation after suxamethonium, fentanyl, droperidol, N2O). The initial bolus dose (ID) of atracurium was 0.25 mg/kg and of vecuronium 0.05 mg/kg followed by repeated increments (RD) of atracurium 0.1 mg/kg and vecuronium 0.0125 mg/kg when neuromuscular function (EMG) had recovered to about 30% of pre-relaxant control. Dose-response relationships revealed atracurium to be about 1/5 as potent as vecuronium; the ED50 of atracurium was 0.13 +/- 0.03 mg/kg and of vecuronium 0.023 +/- 0.007 mg/kg. The ID of both relaxants produced a neuromuscular blockade of about 90% within 4 min. The duration from the time of injection to 30% recovery was slightly longer in atracurium 26 +/- 9 min. In all patients the RD produced within 3.5 min satisfactory muscle relaxation with a neuromuscular block of about 85%. The mean duration of atracurium (18 min) was 5-10 min longer than of vecuronium (12 min). To maintain good surgical relaxation (more than 70% blockade) atracurium 0.32 mg/kg X h and vecuronium 0.056 mg/kg X h were required. No cumulation could be measured after repeated injections. The recovery time of atracurium and vecuronium at the end of anaesthesia was 10-12 min. Neither cardiovascular side-effects nor signs of histamine release were observed after both relaxants in our particular dose range. It is concluded, that atracurium is a favourable blocker for anaesthetic practice: The time of onset is approximately the same compared with vecuronium. The duration of action, however, is slightly longer but still truly intermediate long.(ABSTRACT TRUNCATED AT 250 WORDS)
Kube
D
D
Schuh
F T
FT
D000768:Anesthesia, General; D001279:Atracurium; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004576:Electromyography; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007546:Isoquinolines / Q000008:administration & dosage* / Q000378:metabolism; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D009466:Neuromuscular Blocking Agents / Q000008:administration & dosage* / Q000378:metabolism; D009469:Neuromuscular Junction / Q000187:drug effects; D010197:Pancuronium / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000378:metabolism; D009435:Synaptic Transmission / Q000187:drug effects; D014673:Vecuronium Bromide
D007546:Isoquinolines; D009466:Neuromuscular Blocking Agents; D001279:Atracurium; D014673:Vecuronium Bromide; D010197:Pancuronium
Atracurium: Die neuromuskuläre Blockade bei wiederholter Gabe.